

- Multiplex sequencing, 86e-2, 86e-3f
 Multipotent stem cells, 90e-2, 453t, 454, 454f
 Multivariate statistical models, 3
 Mumps, **231e-1**
 clinical features of, 231e-2-3, 231e-2f
 complications of, 231e-2-3, 893
 diagnosis of, 231e-3
 differential diagnosis of, 231e-3
 epidemiology of, 231e-1-2
 etiology of, 231e-1, 231e-1f
 global considerations in, 231e-1, 231e-1f
 immunity to, 231e-4
 incidence pre- and postvaccine, U.S., 785t
 meningitis in, 908t
 orchitis in, 2365
 pathogenesis of, 231e-2
 prevention of, 231e-3-4. *See also* Measles-mumps-rubella vaccine (MMR)
 transmission of, 231e-2
 treatment of, 231e-3
 Munchausen syndrome, 2719
 Mupirocin
 action of, 931t, 932, 932f
 in burn patients, 166e-3
 for impetigo, 967
 indications for, 941t
 nasal, in staphylococcal skin infections, 345
 prophylactic, 945t
 resistance to, 931t, 934, 941t
 Mu receptors, 468e-1, 468e-1t, 468e-2f
 Murine (endemic) typhus. *See* Endemic (murine) typhus
 Murmurs. *See* Heart murmurs
 Murphy's sign, 283, 2080
 Murray valley encephalitis virus, 1306t
 Murutucú virus, 1309t
 Muscarinic agonists, 473e-10t
 Muscle(s)
 atrophy of, 462e-3-4
 electrophysiologic studies of. *See* Electromyography (EMG)
 enlargement of, 462e-3
 fatigability of, 152, 154
 response to repetitive nerve stimulation, 442e-5-6
 Muscle biopsy
 in central core disease, 462e-12
 in dermatomyositis, 2200f
 in inclusion body myositis, 2201f
 in mitochondrial DNA diseases, 85e-5f, 85e-7
 in muscular dystrophy, 462e-6
 in myopathies, 462e-5
 in polymyositis, 2200f
 Muscle bulk, 154
 Muscle compartment syndrome, 2738
 Muscle contracture, 462e-3
 Muscle cramps, 462e-2-3, 479e-2, 1824
 Muscle disorders
 calcium channel, 462e-16-17, 462e-17f, 462e-17t
 chloride channel, 462e-18
 energy metabolism, 462e-14-15. *See also* Glycogen storage diseases
 muscle fiber. *See* Myopathy(ies)
 muscular dystrophy. *See* Muscular dystrophy
 potassium channel, 462e-17t, 462e-18
 sodium channel, 462e-17-18, 462e-17f, 462e-17t
 Muscle dysphoria syndrome, 7e-2
 Muscle-eye-brain disease, 462e-9, 462e-10t
 Muscle pain, 462e-2, 462e-4t
 Muscle phosphorylase deficiency (McArdle's disease; type V GSD), 433e-2t, 433e-4, 462e-14
 Muscle phosphorylase kinase deficiency, 433e-2t
 Muscle relaxants, 119, 377, 473e-9t, 473e-10t
 Muscle spindle, 155f
 Muscle stiffness, 462e-3
 Muscle strength, 71, 74f, 2220, 2538
 Muscle stretch (tendon) reflexes, 154, 154t, 155f, 2538
 Muscle tone, 154, 154t, 2538
 Muscle wasting, 81, 1268, 1704
 Muscle weakness. *See* Weakness
- Muscular dystrophy, **462e-1**
 AV conduction block in, 1471, 1471t
 Becker's. *See* Becker's muscular dystrophy
 clinical features of, 462e-1-4, 462e-3f
 congenital, 462e-9, 462e-10t
 diagnosis of, 462e-1f, 462e-2f, 462e-3t, 462e-4-5
 Duchenne's. *See* Duchenne's muscular dystrophy
 Emery-Dreifuss. *See* Emery-Dreifuss muscular dystrophy
 facioscapulohumeral, 462e-1, 462e-2f, 462e-5t, 462e-11
 gait disorders in, 163
 genetic considerations in, 434, 436, 436t
 limb-girdle, 462e-6, 462e-6t, 462e-7t
 myotonic. *See* Myotonic dystrophy
 oculopharyngeal, 208, 462e-5t, 462e-11
 progressive, 462e-5t
 proteins associated with, 462e-6, 462e-8, 462e-8f, 462e-9f
- Musculoskeletal disorders, **2216**
 approach to the patient, **2216**, 2216t, 2217f, 2218f
 hand pain, 2220-2221, 2220f
 hip pain, 2222, 2222f, 2230
 knee pain, 2221-2222, 2230
 shoulder pain, 2221, 2221f
 arthritis. *See* Arthritis
 articular vs. nonarticular, 2216
 chest discomfort/pain in, 96t, 98
 drug-induced, 2218t
 in the elderly, 2219
 in hemochromatosis, 2516-2517
 history in, 2218-2219, 2218f
 in hospitalized patient, 2219
 hyperlipidemia and, 2242-2243
 imaging in, 2223-2225, 2224t, 2225f
 infections
 actinomycotic, 1089-1090
 in cancer patient, 489-490
 in joints. *See* Infectious (septic) arthritis
 in prosthetic joints. *See* Prosthetic joint infections
 inflammatory vs. noninflammatory, 2215-2217
 laboratory studies in, 2222-2223, 2223t, 2224f
 obesity and, 415e-6
 osteoarthritis
 physical examination in, 2219-2220
 prevalence of, 2216
 in rheumatic fever, 2151
 in sarcoidosis, 2209, 2209f
 SLE and, 2127
 in systemic sclerosis, 2162
 terminology related to, 2219t
 Mushrooms, poisonous, 267, 283, 473e-9t, 473e-10t
 Mushroom worker's lung, 1681t
 Musk ambrette, 388, 389t
 MuSK antibodies, 2702
 Mussels, contaminated, 2743
 Mustard gas, 262e-1t, 506
 MUT4 gene mutations, 539
 Mutation(s), **432**. *See also* specific genes
 alleles, 435
 allelic heterogeneity in, 435
 in cancer cells, 102e-1. *See also* Cancer genetics
 chromosomal disorders. *See* Chromosome abnormalities/disorders
 definition of, 432
 dynamic, 434
 functional consequences of, 434-435
 genotypes, 435
 identifying, 442-445, 443t
 imprinting of, 439
 locus heterogeneity in, 435-436, 436t
 in Mendelian disorders. *See* Mendelian disorders
 mitochondrial. *See* Mitochondrial DNA diseases
 mosaicism in, 439
 nucleotide repeat disorders, 440, 440t
- origins and types of, 432-434, 433f
 penetrance of, 437
 phenocopies, 436
 phenotypes, 435
 phenotypic heterogeneity in, 435, 436t
 rate of, 433
 sex-influenced, 437
 somatic, 440
 uniparental disomy in, 439
 variable expressivity of, 436-437
 in viruses, 214e-5
 X-inactivation of, 439
- Mutation accumulation theory of aging, 94e-2
 Mutator phenotype, 101e-2
 Mutism, 179
 Mutualist, 86e-1
 MVAC regimen, 577
 MWS. *See* Muckle-Wells syndrome (MWS)
 Myalgia, 462e-2, 462e-4t
 Myasthenia gravis, **2701**
 APS-2 and, 2346t, 2347t
 autoantibodies in, 372e-24t, 377e-4, 2701
 vs. botulism, 989
 clinical features of, 157, 2701-2702
 diplopia, 208
 dysphagia, 257
 dyspnea, 47e-2
 nystagmus, 210
 ocular, 2701-2702
 ptosis, 41e-1v, 207
 weakness, 156, 157, 2701-2702
 congenital syndromes of, 2702, 2703t
 diagnosis of, 2702-2703, 2702t, 2703t, 2704t
 differential diagnosis of, 2702-2703
 disorders associated with, 2703-2704, 2704t
 drug-induced, 462e-20
 drugs to avoid in, 2706, 2706t
 HLA gene association with, 373e-8t
 muscle response to repetitive nerve stimulation in, 442e-6
 pathophysiology of, 2701, 2701f
 pemphigus and, 371
 prevalence of, 2701
 pulmonary function values in, 306e-5, 306e-5f
 reflex responses in, 154
 thymoma and, 123e-2, 2348
 treatment of, **2704**
 algorithm for, 2704f
 assessment of response to, 2706, 2706f
 cholinesterase inhibitors, 2704
 immunosuppressants, 2705
 IVIg, 2705-2706
 plasmapheresis, 2705
 thymectomy, 123e-2, 2704
- Myasthenic crisis, 2706
 Myasthenic fatigue, 2701
 MYB gene mutations, 101e-2t
 Mycetoma, 228, 308e-17f, 1090
 MYC gene, 454
 MYC gene mutations, 101e-3t, 508
Mycobacterium abscessus, 205e-9, 776-777, 1132
Mycobacterium africanum, 1103
Mycobacterium avium complex (MAC)
 infections
 bronchiectasis, 1694, 1696. *See also* Bronchiectasis
 diagnosis of, 1131
 disseminated, 1129-1130
 in HIV infection, 269, 1131, 1251t, 1254
 vs. IBD, 1956
 lymphadenopathy, 1130
 prophylaxis for, 1251t
 pulmonary, 1130
 treatment of, 205e-8, 1131-1132
Mycobacterium bovis, 1103
Mycobacterium bovis bacille Calmette-Guérin. *See* Bacille Calmette-Guérin (BCG) vaccine
Mycobacterium canettii, 1103
Mycobacterium chelonae infections, 205e-9, 829
Mycobacterium fortuitum infections, 205e-9
Mycobacterium spp. infections
 arthritis, 836
 chronic meningitis, 907t